Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Replimune’s twice-rejected melanoma drug prevails in FDA adcomm" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include WSJ and FirstWord Pharma. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 5h ago.
Quick answers
Why is "Replimune’s twice-rejected melanoma drug prevails in FDA adcomm" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Opinion WSJ · 1d ago
- Replimune's oncolytic immunotherapy clears FDA panel despite trial flaws FirstWord Pharma · 1d ago
Topics
Related trends
Nearly 12 million bottles of Rohto eye drops over sterility concerns, FDA announces
The FDA announces a recall of nearly 12 million bottles of Rohto eye drops due to sterility concerns.
Fruit sold at Publix sickens multiple people in 8 states
Publix recalls frozen berries across multiple states following an E. coli outbreak that has sickened consumers.
New, more efficient pill to lower cholesterol
The FDA approves the first oral PCSK9 inhibitor for adults with high cholesterol.
FDA Panel Votes In Favor of Replimune’s Melanoma Treatment
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
FDA Announces Recall on Berries Sold in 8 States for Potential E. Coli Contamination
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
More cases reported in cyclospora outbreak not linked to lettuce: FDA data
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.